Department of Cardiology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark.
Department of Nephrology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark.
J Am Heart Assoc. 2024 Jan 2;13(1):e031019. doi: 10.1161/JAHA.123.031019. Epub 2023 Dec 29.
In patients undergoing transcatheter aortic valve replacement (TAVR), the impact of acute kidney injury (AKI) on the prognosis and especially on future kidney function has been sparsely examined, and data from large cohorts are warranted.
With Danish nationwide registries, we identified all patients undergoing TAVR from 2014 to 2021 with no previous dialysis treatment. According to 2 plasma creatinine samples, we identified those suffering a postprocedural AKI within 21 days after TAVR. With 1 year of follow-up, we compared the associated rates of dialysis treatment and death between patients with and without an AKI using multivariable Cox analysis. Finally, according to the lowest recorded creatinine sample, we assessed the kidney function among AKI survivors between 90 and 180 days after the index date. We identified 4091 TAVRs: 193 (4.7%) with AKI (55.4% men; median age, 82 years) and 3898 (95.3%) without AKI (57.0% men; median age, 81 years). Compared with those without AKI, patients with AKI showed increased associated 1-year rates of dialysis treatment (hazard ratio [HR], 7.20 [95% CI, 4.10-12.66]) and death (HR, 2.39 [95% CI, 1.59-3.58]). After 6 months, 74% of AKI survivors had complete kidney recovery, 14.7% had incomplete kidney recovery, 6.3% failed to recover, and 5.1% were on dialysis treatment.
We identified that AKI after TAVR was associated with an increased rate of future dialysis treatment and all-cause death. Among survivors, 74% had complete kidney recovery within 6 months.
在接受经导管主动脉瓣置换术(TAVR)的患者中,急性肾损伤(AKI)对预后的影响,特别是对未来肾功能的影响,研究甚少,需要大样本队列的数据。
我们利用丹麦全国性登记处,确定了 2014 年至 2021 年期间所有未接受过透析治疗的 TAVR 患者。根据 2 次血浆肌酐样本,我们确定了 TAVR 后 21 天内发生术后 AKI 的患者。通过 1 年的随访,我们使用多变量 Cox 分析比较了 AKI 患者和无 AKI 患者的透析治疗和死亡率。最后,根据最低记录的肌酐样本,我们评估了 AKI 存活者在指数日期后 90-180 天之间的肾功能。我们确定了 4091 例 TAVR:193 例(4.7%)发生 AKI(55.4%为男性;中位年龄 82 岁)和 3898 例(95.3%)无 AKI(57.0%为男性;中位年龄 81 岁)。与无 AKI 患者相比,AKI 患者 1 年时的透析治疗相关发生率(风险比 [HR],7.20[95%CI,4.10-12.66])和死亡(HR,2.39[95%CI,1.59-3.58])均升高。6 个月后,74%的 AKI 存活者完全恢复了肾功能,14.7%的患者不完全恢复了肾功能,6.3%的患者未能恢复,5.1%的患者需要透析治疗。
我们发现 TAVR 后 AKI 与未来透析治疗和全因死亡风险增加相关。在存活者中,74%的患者在 6 个月内完全恢复了肾功能。